All lobbying filings

THE NICKLES GROUP, LLC

THE NICKLES GROUP, LLC filed a Q3 report for MERCK & CO. INC. on October 19, 2026, reporting $70,000 in lobbying income.

Lobbying for MERCK & CO. INC. · Manufacturer of pharmaceuticals

All filings by THE NICKLES GROUP, LLC · Everything MERCK & CO. INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs.

Bills named in this filing 2

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.